Page last updated: 2024-11-12

n-hexanoyldihydrosphingosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-hexanoyldihydroceramide : A dihydroceramide in which the ceramide N-acyl group is specified as hexanoyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16219163
CHEMBL ID224878
CHEBI ID76226
SCHEMBL ID6236415
MeSH IDM0473719

Synonyms (21)

Synonym
dihydroceramide c6, solid
171039-13-7
(2s,3r)-dihydroceramide
n-hexanoyldihydrosphingosine
CHEMBL224878
chebi:76226 ,
n-[(2s,3r)-1,3-dihydroxyoctadecan-2-yl]hexanamide
c6 dihydroceramide
n-hexanoyl-sphinganine
c6-dihydroceramide
n-hexanoyldihydroceramide
n-hexanoylsphinganine
SCHEMBL6236415
DTXSID40585109
c6 dihydroceramide (d18:0/6:0), n-hexanoyl-d-erythro-sphinganine, powder
c6 dihydroceramide [n-hexanoylsphinganine]
mfcd01320384
Q27145820
n-((2s,3r)-1,3-dihydroxyoctadecan-2-yl)hexanamide
c6 dihydro ceramide (d18:0/6:0)
BP-28808

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" We conclude that C6-Cer complexed to CholPC increased the bioavailability of the short-chain ceramide for cells, and potentiated its effects in comparison to solvent-dissolved C6-Cer."( Complexation of c6-ceramide with cholesteryl phosphocholine - a potent solvent-free ceramide delivery formulation for cells in culture.
Långvik, O; Lönnfors, M; Pulli, I; Slotte, JP; Sukumaran, P; Törnquist, K, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acylsphinganineA ceramide consisting of sphinganine in which one of the amino hydrogens is substituted by a fatty acyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID526975Metabolic stability in human MCF7 cells assessed as cellular dihydrsphingosine levels at 40 uM after 24 hrs by LC-MS/MS analysis relative to control2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526971Metabolic stability in human MCF7 cells assessed as cellular C6-dihydroceramide levels at 40 uM after 24 hrs by LC-MS/MS analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526776Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth at 10 uM after 24 hrs by trypan blue exclusion assay2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526969Metabolic stability in human MCF7 cells assessed as cellular dihydroceramide levels at 40 uM after 24 hrs by LC-MS/MS analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526974Metabolic stability in human MCF7 cells assessed as C16-ceramide levels at 40 uM after 24 hrs by LC-MS/MS analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526970Metabolic stability in human MCF7 cells assessed as cellular C16-dihydroceramide levels after 24 hrs by LC-MS/MS analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526773Antiproliferative activity against human MCF7 cells after 24 hrs by trypan blue exclusion assay2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526968Metabolic stability in human MCF7 cells assessed as cellular dihydroceramide levels at up to 10 uM after 24 hrs by LC-MS/MS analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID284355Cytotoxicity against human A549 cells upto 1 mM in presence of 10% FBS after 72 hrs by MTT test2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Solid-phase synthesis of a combinatorial library of dihydroceramide analogues and its activity in human alveolar epithelial cells.
AID526976Metabolic stability in human MCF7 cells assessed as cellular dihydrsphingosine levels at 10 uM after up to 5 hrs by LC-MS/MS analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.47 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]